We are committed to addressing unmet needs in serious mental illness through the development of therapeutic options to support adults living with schizophrenia and bipolar I disorder.
The Alkermes Pathways Research Awards are open for applications! This program is open to all early-career investigators studying bipolar disorder or schizophrenia.
April marks National Minority Health Month, a time for us to reflect on the work still needed to address and break down existing barriers that keep minority communities from seeking mental health care.
Our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found that a vast majority of respondents who live with bipolar I disorder experienced medication side effects that negatively impacted their daily lives.
Results from our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found an overwhelming majority of patients surveyed with bipolar 1 disorder felt it is a difficult and isolating experience.
May is Mental Health Month! The COVID-19 pandemic has put mental health front and center. This month we encourage everyone to learn more, share resources, and consider how you can support those who are living with mental illness.
This National Minority Health Month, we’re learning more about the disproportionate prevalence of mental illness, socioeconomic disparities & barriers to care in minority communities.
Dr. Rakesh Jain and Dr. Andrew Cutler guest hosted the Alkermes-sponsored MDEdge Psychiatry podcast to discuss the management of comorbidities & behavioral risk factors that may be present in people living with schizophrenia.
Responsible Business & Employee Engagement
| Alkermes
Meet Jessica Tamborski -- an Alkermes employee inspired by her daughter’s struggle with bipolar disorder who is proud to work at an organization that helps people living with serious mental illness.
Our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found that a vast majority of respondents who live with bipolar I disorder experienced medication side effects that negatively impacted their daily lives.
Alkermes is committed to understanding the unique needs of people living with mental illness and supporting disease awareness and education. We know there’s much to be done.
Results from our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found an overwhelming majority of patients surveyed with bipolar 1 disorder felt it is a difficult and isolating experience.
Results from a newly released survey provide insights from adults living with bipolar I disorder in the United States on the burden of living with this serious mental health condition and their experiences with treatment.
Jessica Veri is an Alkermes employee whose personal connection to mental health inspires her to make a meaningful difference in the lives of people living with serious mental illness.
May is Mental Health Month! The COVID-19 pandemic has put mental health front and center. This month we encourage everyone to learn more, share resources, and consider how you can support those who are living with mental illness.
Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May.
Alkermes plc (Nasdaq: ALKS) recently announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society (SIRS), taking place virtually April 17-21, 2021.
Alongside the The STARR Coalition, we recognize the need to support mental health research. Scientific, evidence-based mental health research is essential.
Alkermes is committed to diversity, inclusion and belonging in various aspects of our business. We are purposeful about creating an environment that...